GAITHERSBURG, Md. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax , Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn , M.D, President of Research & Development, will present on NVX-CoV2373,...

Team w ill focus on global NanoFlu licensure and evaluation of post-pandemic influenza/COVID-19 combination vaccine with NVX-CoV2373 Russell (Rip) Wilson promoted to Executive Vice President and NanoFlu General Manager GAITHERSBURG, Md. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....

GAITHERSBURG, Md. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in four upcoming investor and industry conferences....

GAITHERSBURG, Md. , Sept. 28, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the...

Clinical trial to enroll up to 10,000 volunteers across the UK to assess whether NVX-CoV2373 is effective in the prevention of COVID-19 GAITHERSBURG, Md. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for...

Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021 Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in 2021 Agreement expands Novavax partnership with world’s largest vaccine developer to increase global...

GAITHERSBURG, Md. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences....

-- Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines -- NEW YORK --(BUSINESS WIRE)--Sep. 8, 2020-- The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX),...

NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera GAITHERSBURG, Md. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines...

•   Canadian government to purchase up to 76 million doses of NVX-CoV2373 GAITHERSBURG, Md. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an...